Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

How Lilly Oncology is aiming to improve clinical trial diversity

By Brian Buntz | September 16, 2021

Eli LillyMinorities tend to participate in clinical trials at far lower rates than their real-world demographics and prevalence of the disease, according to the American Society of Clinical Oncology. In addition, minorities often have worse outcomes for certain cancers than the broader public. Just one example: the mortality rate for Black women with breast cancer is 40% higher than that of white women.

The pandemic, however, has highlighted persistent health disparities while offering potential strategies for improvement, according to Amy Davis, senior director of clinical development at Lilly Oncology.

The pandemic has popularized the use of decentralized trials. Lilly debuted decentralized capabilities in a recent breast cancer trial and will continue doing so for upcoming trials.

“We are building in decentralized capabilities from the get-go, decreasing the number of in-person visits by half,” Davis said.

The company is using remote data capture and offering more telemedicine visits to optimize enrollment. Lilly is also aiming to identify strategies to simplify how patients receive scans and lab testing.

Amy Davis

Amy Davis

When working to expand decentralized trial capabilities, companies like Lilly are also forced to confront the digital divide and varying expectations from clinical trial participants.

“Not every group of patients is going to want people in their home or want to do virtual visits,” Davis said. “It is going to be a delicate balance. I think we’re going to need rapid learning cycles to understand what’s working and what’s not.”

The beauty of decentralized trials is that they enable drug developers to reach new patients in rural areas or urban areas who may not live close to an academic medical center.

“Having decentralized trials allows these patients to participate in research and allows us to have more diversity because as a result,” Davis said.

The pandemic has also resulted in a greater collaborative focus on diversity across the industry and in regulatory agencies and advocacy groups.

For instance, Lilly is working with the decentralized research organization Care Access Research (Boston) to help reduce the barriers of entry for oncologists and other specialists in remote areas who are interested in enrolling patients in clinical trials. Care Access also offers a geo-mapping service to find concentrations of patients who lack an option to participate in clinical trials.

The work with Care Access “helps twofold with our goals,” Davis said. “We not only want to increase the diversity of patients in our trials, but we also want to increase the diversity of the investigators we’re working with. And so this allows us the opportunity to do both.”

Lilly is also partnering with clinical optimization software company Reify Health (Boston) to screen patients interested in joining new clinical trials. The partnership helps Lilly keep tabs on the diversity of such patients while also keeping track of why potential participants are screening out. The latter can inform the inclusion criteria of future clinical trials to optimize for diversity.

“Reviewing eligibility criteria is critical because we know that minorities are more likely to have multiple health conditions than whites,” Davis said. “So if you’re excluding folks who have other health conditions by default, you’re disproportionately excluding [diverse] populations.”

In the long run, Davis said the pharmaceutical industry must continue to confront a handful of themes to continue making progress in clinical trial diversity.

“The first is addressing lack of trust,” she said. “You build trust through working with more physicians and investigators who look like the patients you’re trying to recruit,” she added.

The pharmaceutical industry also needs to continue to reduce barriers to clinical trial access through decentralization and other strategies.

“We’re going to have to locate trials where patients are and offer more virtual visits, so people don’t have to travel or take time off of work or have an unnecessary burden,” Davis said.

Another way the pharmaceutical industry can build stronger relationships with diverse populations is through partnerships with advocacy organizations and trusted intermediaries.

“One of the things that we learned in COVID is that you have to go to your churches, you have to be on radio stations that these populations listen to, and you have to be with their local health care providers and those trusted intermediaries in their community,” Davis said.


Filed Under: clinical trials, Drug Discovery, Oncology
Tagged With: coronavirus, covid-19, diversity, Eli Lilly, Eli Lilly & Co., oncology, pandemic
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE